Peter Cashin retweeted
Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial @aecirujanos @PSOGI_EC @indepso @GrupoTTD @ISSPP1 academic.oup.com/bjsopen/art…
Reinforced tension-line suture after laparotomy: long-term results of Rein4CeTo1 randomized clinical trial
➡️doi.org/10.1093/bjsopen/zraf…
The aim of this randomized clinical trial was to investigate whether a reinforced tension-line (RTL) suture reduces 3-year computed tomography-detected incisional hernia incidence. The RTL technique significantly reduced the incidence of incisional hernia compared with the standard facial closure technique in patients undergoing open colorectal cancer surgery. The incisional hernia incidence was 6 of 43 (14%) in the RTL and 21 of 58 (36%) in the standard facial closure group.
👏👏👏Charlotta L Wenzelberg , Peder Rogmark , Olle Ekberg , Ulf Petersson , Carl-Fredrik Rönnow
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery @eurohernias #hernia #hernia @herniaistanbul @BritishHernia @HerniaIndia @awrsurgeons
Peter Cashin retweeted
Is it sexy? No.
Is it incredibly important for how we treat patients? Absolutely 🧠🧬
For over 20 years, 6 months of oxaliplatin plus a fluoropyrimidine has been the default for stage III colon cancer, and often high-risk stage II and rectal cancer. The cost has always been cumulative neuropathy that can follow patients for life ⚡️🖐️
The SCOT trial, the largest study in the IDEA collaboration, gives us long-term clarity with nearly 6,100 patients and more than 6 years of follow-up:
📊 5-yr DFS identical with 3 vs 6 months: 72.9% vs 72.9%
📈 5-yr OS identical: 82.4% vs 82.4%
✅ Noninferiority for OS formally met for 3 months
Where this really matters clinically:
🟢 CAPOX clearly supports 3 months
🟢 Low-risk stage III shows no OS penalty
🟡 Even high-risk disease sees only tiny absolute OS differences
⚠️ Meanwhile, neuropathy nearly doubles when oxaliplatin is extended to 6 months. Many patients pay a lifelong price for minimal benefit.
SCOT also uniquely included rectal cancer patients treated with upfront surgery, and here too, 3 months held up. This fits perfectly with modern TNT strategies 🧩
Takeaway:
This isn’t flashy, but it’s foundational. For most patients with localized colon or rectal cancer, 3 months of adjuvant CAPOX is enough. Six months should be the exception, not the rule, and always a shared decision 🤝
Sometimes the most important advance is knowing when to stop.
@OncoAlert @TheGutOncLab
#GI26
ascopubs.org/doi/pdf/10.1200…
Peter Cashin retweeted
Ultraprocessed foods increase risk of early-onset colorectal cancers
@JAMA_current
@TataMemorial @ACTREC_TMC @CRI_ACTREC @CCAlliance @ColorectalDis @escp_tweets @ACPGBI @ASCRS_1
jamanetwork.com/journals/jam…
Peter Cashin retweeted
#AudioVisualAbstract : Patterns of Preoperative #TumorMarkers Can Predict Resectability and Prognosis of #PeritonealMetastases : A Clustering Analysis
rdcu.be/eOgg9
@scalpelmomma
@SyedAAhmad5
Peter Cashin retweeted
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Elinor Bexe Lindskog 🇸🇪
The Immune Microenvironment in Peritoneal Metastases
The immune landscape of peritoneal metastases differs from other metastatic sites. Peritoneal lesions show a fibro-inflammatory, immune-regulated niche with activated yet restrained T cells — key to future therapeutic strategies.
@BexeLindskog
@jzager99 @moffittnews
@LauraLorenzonMD
@WimCeelen
@Surgeonjakob
@itrisabel
@SOS_Pk
@hjmajid
@martajimenez135
@OlofssonBagge
@AndreasBrandl8
@GabrielleVanRam
@ESSOnews
Peter Cashin retweeted
#DCRJournal visual abstract | Insights Into the Group of Surgically Resectable But Nonoperable Patients With Colorectal Cancer: bit.ly/41lKcfS
Peter Cashin retweeted
#DCRJournal visual abstract recap | Efficacy of Traditional Acupuncture Compared to Biofeedback Therapy in Fecal Incontinence: A Randomized Controlled Trial: bit.ly/4eiBtzB
@SeanLangenfeld @changtangMD @luciacolorectal @deanlute @juliomayol
Peter Cashin retweeted
This 4-year analysis of data from the LASER RCT demonstrates a high crossover rate to surgery for patients with low GI Quality of Life scores. ja.ma/3GbbJdn
Peter Cashin retweeted
Excellent review/ debate
Published open access 🔓
A must read for all those treating colorectal PM
@CashinPtr @WimCeelen @KurtSpeeten @alarjosan @AndreasBrandl8 @FarazKh65499316 @ANikiforchin @LFallaZuniga @DrFloresAyala @MufaddalKazi @vivekanandkem @DrSGlezMoreno @RupenShahMD @kturaga
Fresh out of the oven! Great read: HIPEC for Colorectal peritoneal Mets @AnnSurgOncol
link.springer.com/article/10…
@uchicagosurgery @UChicagoMed @UChiPritzker
Jason M Foster Garrett Nash
Peter Cashin retweeted
PS are delighted to welcome Maddy Lomas to the Board of Trustees. A PMP patient herself, she is passionate about helping younger patients navigate a cancer diagnosis. ABB is smiling, and we look forward to working with you Maddy.
Susan, Anne, Clare & Tim - PS Board of Trustees.
Peter Cashin retweeted
30y after @PSugarbaker s orginal 📜, 🆕revised classification of peritonectomy procedures + def of nomenclatures & boundaries-📰 in @BJSAcademy @glehenolivier
🔓 doi.org/10.1093/bjs/znaf112
Congrats @PSOGI_EC @ESGO_society @ISSPP1 panel
Imp👣 for standardizing CRS+ research in PSM
Peter Cashin retweeted
#AjinkyaPawar – Shared cutting-edge insights on 🫁 𝗺𝗲𝘁𝗮𝘀𝘁𝗮𝘀𝗲𝘀 𝗶𝗻 𝗖𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝘄𝗶𝘁𝗵 𝗽𝗲𝗿𝗶𝘁𝗼𝗻𝗲𝗮𝗹 𝗺𝗲𝘁𝗮𝘀𝘁𝗮𝘀𝗲𝘀 and #training in PSM, highlighting the next frontier in surgical oncology. 🧑🏫
@docswapnil01 - spoke on the important topic of optimizing 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 for 𝗽𝗿𝗶𝗺𝗮𝗿𝘆 𝗮𝗻𝗱 𝗶𝗻𝘁𝗲𝗿𝘃𝗮𝗹 𝗰𝘆𝘁𝗼𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗼𝘃𝗮𝗿𝗶𝗮𝗻 𝗰𝗮𝗻𝗰𝗲𝗿. ⚖️
@ESSOnews @SPeritoneum @IJGConline
Peter Cashin retweeted
Replying to @PMPSurvivor
Brilliant justification for a logo!! Indeed, our patients are recognized by the abscence of their belly button!
Peter Cashin retweeted
A rare appendix cancer is surging among people born in the 1980s and later, with rates for younger people up to four times higher than those born in the 1940s, a new study found. More: tinyurl.com/rv84y95e
Peter Cashin retweeted
🔊 🔊 Calling on young surgeons/ clinicians around the 🌎 🌏
If you are conducting a clinical trial/ cohort study 📈 📉 or have an idea 🌪️ that you would like to share 👩🏫 👨🏫 with the PSM community
'Pitch your trial idea' to #PSOGI2025 #PSOGIBarcelona
and participate in this very innovative contest by @LanaBijelicMD @DrSGlezMoreno #PereBretcha #FernandoPereira
More details psogicongress2025.com/pitch-…
✳️ Eligibility: Surgeon </=45 years, PI or Co-investigator in the proposed trial
✳️ Type of study: Prospective cohort/registry study or Clinical Trial
🔴 Submission deadline: July 1, 2025 📅
🔴 Important: Registration for the PSOGI 2025 Congress is mandatory
@FarazKh65499316 @AndreasBrandl8 @indepso @ISSPP1 @SPeritoneum @me4_so @elfasaco @kturaga @NewsJellybelly @arslannc_md @ANikiforchin @AssocAmarape @NewsJellybelly @Ginibala @LFallaZuniga @CashinPtr @dr_mohammadyami @IJGConline @IJGCfellows @ESGO_society @docswapnil01 @safichintan @Deeplamichhane3 @IndianYoungOnco @ejsotweets @SocSurgOnc
Peter Cashin retweeted
🚨 ESSO is looking for a melanoma surgeon!
Join the Education & Training Committee’s Endocrine/Melanoma/Sarcoma Working Group.
🔹 Shape educational strategy
🔹 Lead webinars, courses, EBSQ prep
🔹 2-year term, renewable
🔹 Deadline: 31 July 2025
📩 Apply: essoweb.org/news/esso-ect-ca…
Peter Cashin retweeted
🏆A celebration of excellence in surgical science, the BJS Award recognises a discovery, innovation or scientific study that has changed clinical practice.
This international accolade will give an exceptional individual the recognition they richly deserve for the profound impact they have had on patient care.
The Award forms part of the BJS Foundation’s international outreach programme. They have therefore pledged to donate to surgical educational development and the BJS Foundation Charity Committee.
🎥 Watch the 2025 Award Ceremony LIVE – 13 June at 18:15 BST
🔗 youtube.com/live/UsLsUsUgimg…
📱 Join our WhatsApp Communities for reminders:
➡️chat.whatsapp.com/BkfTZJYJyN…
#ShapingSurgicalScience #LeadingSurgicalEducation @BJSurgery @BjsOpen @JJEarnshaw
Peter Cashin retweeted
The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival.
Perfect case example of a #cancergroundshot trial.
nejm.org/doi/full/10.1056/NE…






































